Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma (TNT Esophagus)
A Single-arm Study of Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma
The goal of this trial is to learn if adding consolidative chemotherapy to routine chemoradiation can better control both local recurrence and metastasis and reduce the need for surgical intervention.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Clinical Trials Office
- 电话号码:(919) 668-3726
- 邮箱:RadOnc-Clinical_Trials@dm.duke.edu
学习地点
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- Duke University Medical Center
-
首席研究员:
- Manisha Palta, MD
-
接触:
- Kaitlin Bailey, RN BSN OCN
- 电话号码:(919) 668-3726
- 邮箱:RadOnc-Clinical_Trials@dm.duke.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Subject must be able to provide study specific informed consent prior to study entry
- Must be newly diagnosed, histologically proven diagnosis of adenocarcinoma of the thoracic esophagus or gastroesophageal junction (Siewert I-II);
- Stage II-IVA, excluding T4b, according to the American Joint Committee on Cancer (AJCC) 8th edition;
- Complete history and physical examination within 21 days of signing consent;
- Staging whole-body FDG-PET/CT (fluorodeoxyglucose-positron emission tomography/computed tomography) scan with or without contrast (preferred) or chest/abdominal (CT with contrast) confirming there is no evidence of metastatic disease must be obtained within 45 days of study enrollment
- ECOG (Eastern Cooperative Oncology Group) performance status of 0-2
- Subjects must be appropriate candidates for planned chemoradiation (concurrent carboplatin/paclitaxel) and chemotherapy (FLOT, m-FOLFOX-6) as determined by the treating radiation oncologist, medical oncologist, and surgical oncologist.
- Adequate hematologic, renal, and hepatic function within 14 days of initiation of therapy
Exclusion Criteria:
-
Cervical esophageal cancers arising 15-18 cm from the incisors.
-
Esophageal squamous cell carcinoma.
-
Patients with T4b disease according to the AJCC 8th Edition.
-
Definitive clinical or radiologic evidence of metastatic disease.
-
Has had prior systemic therapy or radiation therapy for the current diagnosis.
-
Prior thoracic radiotherapy for any reason that would result in overlap of radiation therapy fields; all patients with prior radiotherapy must be reviewed by the PI to determine if patient is eligible.
-
Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
-
Severe, active co-morbidity defined as follows:
- Active uncontrolled infection requiring IV antibiotics;
- Pregnant and/or nursing subjects;
- HIV positive with CD4 count < 200 cells/microliter. Note that subjects who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count ≥ 200 cells/microliter within 30 days prior to registration. Note also that HIV testing is not required for eligibility for this protocol. This exclusion criterion is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
-
Has a history or current evidence of physical or physiological contraindication to participation in this study, at the discretion of the treating investigator.
-
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Chemoradiation with consolidative chemotherapy
Participants will receive a standard course of chemoradiation followed by consolidative chemotherapy (FOLFOX regimen at the treating physician's discretion). |
Modified-FOLFOX-6 or FLOT (Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with Clinical complete response (cCR)
大体时间:approximately 36 weeks
|
cCR defined as absence of malignancy on endoscopic biopsies obtained at the time of reassessment following neoadjuvant therapy |
approximately 36 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants who complete both chemoradiation and chemotherapy
大体时间:approximately 36 weeks
|
approximately 36 weeks
|
|
|
Number of participants with pathologic complete response (pCR)
大体时间:approximately 36 weeks
|
Pathologic complete response (pCR) is defined as absence of detectable tumor of esophagectomy tissues. |
approximately 36 weeks
|
|
Number of participants with local control
大体时间:up to 5 years
|
Local control in participants achieving clinical complete remission (cCR) estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Number of participants with Disease free survival
大体时间:up to 5 years
|
Disease free survival in participants achieving cCR estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Time to distant metastasis
大体时间:up to 5 years
|
Time to distant metastasis in participants achieving cCR estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Overall survival
大体时间:up to 5 years
|
Measured in participants achieving cCR and estimated using the Kaplan-Meier method. cCR is defined as the disappearance of all detectable signs and symptoms of a disease, such as cancer, have completely disappeared. |
up to 5 years
|
|
Number of participants with Local control
大体时间:up to 5 years
|
Measured in participants achieving pCR and estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Disease free survival
大体时间:up to 5 years
|
Disease free survival in participants achieving pCR. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Time to distant metastasis
大体时间:up to 5 years
|
Time to distant metastasis in participants achieving pCR estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
|
Overall survival
大体时间:up to 5 years
|
Measured in participants achieving pCR and estimated using the Kaplan-Meier method. pCR is defined as absence of detectable tumor of esophagectomy tissues. |
up to 5 years
|
合作者和调查者
调查人员
- 首席研究员:Manisha Palta, MD、Duke Health
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Pro00120182
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Data may be shared 6 months after publication or as required by the journal
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.